Previous 10 | Next 10 |
ACHR, AGRO, ALT, ASLE, BRT, COUP, CVGW, DLO, ENZ, FINV, GTLB, HOFV, LIFE, LRFC, MHLD, MTN, NOAH, OTC:NWHUF, OPTT, PEI, SLGG, SMFR, WPRT, YALA For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close
aTyr Pharma (NASDAQ:LIFE) is scheduled to announce Q4 earnings results on Monday, March 14th, after market close. The consensus EPS Estimate is -$0.28 (+40.4% Y/Y) and the consensus Revenue Estimate is $2.52M (+22.9% Y/Y). For further details see: aTyr Pharma Q4 2021 Earnings Preview
After a meeting with the U.S. Food and Drug Administration (FDA), the clinical-stage biotech aTyr Pharma (NASDAQ:LIFE) announced on Thursday that the company expected to initiate a registrational study for its lead candidate efzofitimod in Q3 2022 targeting patients with pulmonary sarcoidosis...
SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the positive outcome of a Type...
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming American Asso...
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2021 financial resu...
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Off...
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Offi...
LONDON, UK / ACCESSWIRE / February 22, 2022 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF) , the brand-led consumer goods company focused on CBD health and wellness solutions, is pleased to provide a further corporate update. Board Update As announced on 4 February 2022, Graham Mullis a...
LONDON, UK / ACCESSWIRE / February 22, 2022 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF) , the brand-led consumer goods company focussed on CBD health and wellness solutions, has become the first CBD brand to have a number of its products listed on eBay UK at www.ebay.co.uk. eBay will list...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...